Clinical Trial Update: Efficacy of Nicotine Acid on Dyslipidaemia in Patients With Metabolic Syndrome [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating nicotinic acid (niacin) for dyslipidemia in metabolic syndrome has completed and reports efficacy data.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia
• Metabolic Syndrome

Drugs mentioned

• Niacin (nicotinic acid)

Snippet

Sponsor: GWT-TUD GmbH | Conditions: Metabolic Syndrome, Dyslipidaemia | Phase 3 | Status: COMPLETED